Tajikistan Medical Device Registration: Step-by-Step Process under Law No. 1893

1. Key takeaways

The legal spine of medical device registration in Tajikistan runs through four stages: application submission, expert review, issuance of the registration certificate, and entry into the national register. Article 17(2) of Law No. 1893 governs submission: the manufacturer or its authorized person (the applicant) submits the prescribed list of necessary documents to the State Supervisory Authority for Pharmaceutical Activities in electronic or written form. Article 18 governs review: the supervisory authority conducts the expert review on the basis of a comprehensive evaluation of safety, quality, effectiveness, economic viability and risk. Article 17(6) and Article 17(8) govern issuance and registration: a registration certificate valid for five years is issued, and the supervisory authority enters the registered product into the national register of medicines. GRZAN notes that Article 18 lists economic viability as one of the five evaluation dimensions, a feature that clearly distinguishes the Tajik review framework from most other markets, where only safety, quality and effectiveness are examined. Because the law fixes no deadline for any stage, applicants should plan the full cycle on the basis of practical experience rather than statutory timelines.

2. Legal basis

3. Expert insights

Insight 1: economic viability is a dimension unique to Tajikistan within the five-criteria standard of Article 18(1). Review frameworks in most markets focus on safety, effectiveness and quality; Tajikistan writes economic viability alongside risk into the statute. GRZAN reads this dimension against the national context: more than 90 percent of medicines and medical devices used in the country are imported, and health spending accounts for roughly 7 percent of the state budget (this set of figures is a practical estimate intended to explain policy orientation, not statutory data). The practical consequence for applicants is that the registration dossier should contain an economic case for the product, including a cost comparison with existing treatment options available locally and an analysis of local accessibility, rather than technical conformity evidence alone.

Insight 2: acceptance of electronic or written submission leaves room for digital filing. The wording of Article 17(2) gives electronic submission the same legal effect as paper submission. However, the provision itself does not specify the technical format of electronic submission, the account system, or the requirements for electronic signatures. GRZAN recommends confirming the currently acceptable electronic submission channel with the supervisory authority before filing, so that the dossier is not returned for formal reasons. Keeping written confirmation of the accepted channel also protects the applicant if internal staff or the local representative change during the project.

Insight 3: the power to set review requirements sits with the Ministry of Health, while the power to conduct review sits with the supervisory authority. Article 18(2) grants the rule-making power to the Ministry of Health, while Article 18(1) and Article 9(3) assign implementation to the supervisory authority. This separation matches the allocation of procedure-making power under Article 17(12). When preparing technical documentation, companies should therefore request the review requirements document issued by the Ministry of Health, not from the supervisory authority, and should verify that the version they hold applies to medical devices rather than to medicines only.

Insight 4: Article 17(1) through 17(8) form a complete chain, but without any time nodes. From the registration prerequisite in paragraph 1, to submission in paragraph 2, to issuance in paragraph 6, and to entry in the register in paragraph 8, the law identifies the stages and the responsible bodies but sets no statutory deadline for any of them. This stands in sharp contrast to Kyrgyzstan, where Resolution No. 513 fixes an express limit of 50 calendar days from confirmation of payment. The consequence is that the Tajik registration cycle cannot be derived from the legal text; it can only be estimated from practical experience, and the schedule must carry buffer time.

4. Practical recommendations

1. Add a dedicated economic justification chapter to the registration dossier. Under Article 18(1), GRZAN recommends preparing the economic case as a standalone chapter covering a cost comparison with locally available alternatives, cost per use, maintenance cost and training cost, so that the fifth evaluation dimension is answered directly.
2. Confirm the current electronic submission method before filing. Under Article 17(2), verify with the supervisory authority the channel, format and signature requirements for electronic submission, and retain written confirmation for the project file.
3. Request the review requirements document from the Ministry of Health, not from the supervisory authority. Under Article 18(2), the rule-making power lies with the Ministry of Health; when requesting, specify clearly that the applicable subject is medical devices.
4. Build the schedule on practical estimates and keep buffer time. Because Law No. 1893 sets no statutory review deadline, GRZAN uses practical estimate cycle ranges in project scheduling and reserves at least 2 to 3 months of buffer on the critical path for deficiency responses.

5. Verification checklist

• □ Confirmed the registration prerequisite under Article 17(1)
• □ Determined the applicant entity and the form of submission, electronic or written, under Article 17(2)
• □ Confirmed the current channel, format and signature requirements for electronic submission
• □ Obtained the review requirements document for medical devices issued by the Ministry of Health under Article 18(2)
• □ Added an economic justification chapter to the dossier under the five-dimension standard of Article 18(1)
• □ Estimated the registration cycle on a practical estimate basis and reserved buffer for deficiency responses
• □ Planned to verify entry into the national register under Article 17(8) after the certificate is issued

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com